OrbiMed Amends TELA Bio Stake

TL;DR

OrbiMed just updated their TELA Bio filing - ownership change, details TBD.

AI Summary

OrbiMed Advisors LLC and OrbiMed Capital GP IV LLC have amended their Schedule 13D filing for TELA Bio, Inc. on June 28, 2024. This amendment, the fourth, indicates a change in their beneficial ownership of TELA Bio's common stock. The filing does not specify the exact percentage change or dollar amount involved in this amendment.

Why It Matters

This filing signals a potential shift in significant ownership for TELA Bio, Inc., which could influence the company's stock performance and strategic direction.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings often indicate significant changes in beneficial ownership, which can lead to increased stock volatility.

Key Players & Entities

• OrbiMed Advisors LLC (company) — Filing entity
• OrbiMed Capital GP IV LLC (company) — Filing entity
• TELA Bio, Inc. (company) — Subject company
• June 28, 2024 (date) — Date of event requiring filing

FAQ

Key Financial Figures

• $0.001 — 7,242 shares of common stock, par value $0.001 per share (the " Shares "), of TELA Bio
• $4.74 — OPI IV June 28, 2024 Sold 378,000 $4.74 OPI IV July 1, 2024 Sold 13,700 $
• $4.68 — 4 OPI IV July 1, 2024 Sold 13,700 $4.68 OPI IV July 2, 2024 Sold 36,600 $
• $4.54 — 8 OPI IV July 2, 2024 Sold 36,600 $4.54 (d) Not applicable. (e) Not applicab

Filing Documents

• ss3585186_sc13da.htm (SC 13D/A) — 82KB
• ss3585186_ex9901.htm (EX-99.1) — 5KB
• 0000947871-24-000584.txt ( ) — 89KB

Security and Issuer

Item 1. Security and Issuer This Amendment No. 4 (" Amendment No. 4 ") to Schedule 13D supplements and amends the Statement on Schedule 13D of OrbiMed Advisors LLC and OrbiMed Capital GP IV LLC (the " Statement ") originally filed with the Securities and Exchange Commission (the " SEC ") on November 25, 2019, as amended by Amendment No. 1 filed with the SEC on July 1, 2020, Amendment No. 2 filed with the SEC on August 19, 2022 and Amendment No. 3 filed with the SEC on April 21, 2023. This Statement relates to the common stock, par value $0.001 per share (the " Shares ") of TELA Bio, Inc., a corporation organized under the laws of Delaware (the " Issuer "), with its principal executive offices located at 1 Great Valley Parkway, Suite 24, Malvern, Pennsylvania 19355. The Shares are listed on the NASDAQ Global Market under the ticker symbol "TELA". Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. This Amendment No. 4 is being filed to report that the beneficial ownership of the outstanding Shares held by the Reporting Persons (as defined below) was reduced by more than 1% since the last filing following the transactions described in Item 5(c) below.

Identity and Background

Item 2. Identity and Background (a) This Schedule 13D is being filed by OrbiMed Advisors LLC (" OrbiMed Advisors ") and OrbiMed Capital GP IV LLC (" OrbiMed GP ") (collectively, the " Reporting Persons "). (b) — (c), (f) OrbiMed Advisors, a limited liability company organized under the laws of Delaware and a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member OrbiMed GP, as more particularly described in Item 6 below. OrbiMed Advisors has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022. OrbiMed GP, a limited liability company organized under the laws of Delaware, is the general partner of OrbiMed Private Investments IV, LP (" OPI IV "), a limited partnership organized under the laws of Delaware, as more particularly described in Item 6 below. OrbiMed GP has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022. The directors and executive officers of OrbiMed Advisors and OrbiMed GP are set forth on Schedules I and II, respectively, attached hereto. Schedules I and II set forth the following information with respect to each such person: (i) name; (ii) business address; (iii) present principal occupation of employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; and (iv) citizenship. (d) — (e) During the last five years, neither the Reporting Persons nor any Person named in Schedules I and II has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration Not applicable.

Purpose of Transaction

Item 4. Purpose of Transaction The Shares were originally acquired by the Reporting Persons for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries, (c) a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries, (d) any change in the present Board of Directors or management o

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer (a) — (b) The following disclosure is based upon 24,653,939 outstanding Shares of the Issuer, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 18, 2024 and includes an additional 30,725 Shares subject to currently exercisable Warrants held by the Reporting Persons. As of the date of this filing, OPI IV, a limited partnership organized under the laws of Delaware, holds 2,447,967 Shares, including Warrants to purchase 30,725 Shares, constituting approximately 10.0% of the issued and outstanding Shares. OrbiMed GP is the general partner of OPI IV, pursuant to the terms of the limited partnership agreement of OPI IV, and OrbiMed Advisors is the managing member of OrbiMed GP, pursuant to the terms of the limited liability company agreement of OrbiMed GP. As a result, OrbiMed Advisors and OrbiMed GP share power to direct the vote and disposition of the Shares held by OPI IV and may be deemed directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the Shares held by OPI IV. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI IV. In addition, OrbiMed Advisors and OrbiMed GP, pursuant to their authority under the limited partnership agreements of OPI IV, caused OPI IV to enter into the agreements referred to in Item 6 below. (c) The Reporting Persons effected the following transactions in Shares. Seller Date of Transaction Transaction Number of Shares Price Per Share OPI IV June 28, 2024 Sold 378,000 $4.74 OPI IV July 1, 2024 Sold 13,700 $4.68 OPI IV July 2, 2024 Sold 36,600 $4.54 (d) Not applicable. (e) Not applicable.

Contracts, Arrangements, Understandings or Relationships

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, OrbiMed GP is the general partner of OPI IV, pursuant to the terms of the limited partnership agreement of OPI IV. Pursuant to this agreement and relationship, OrbiMed GP has discretionary investment management authority with respect to the assets of OPI IV. Such authority includes the power to vote and otherwise dispose of securities held by OPI IV. The number of outstanding Shares attributable to OPI IV is 2,437,967 Shares (which includes Shares issuable upon the exercise of Warrants). OrbiMed GP, pursuant to its authority under the limited partnership agreement of OPI IV, may be considered to hold indirectly 2,437,967 Shares (which includes Shares issuable upon the exercise of Warrants). OrbiMed Advisors is the managing member of OrbiMed GP, pursuant to the terms of the limited liability company agreement of OrbiMed GP. Pursuant to these agreements and relationships, OrbiMed Advisors and OrbiMed GP have discretionary investment management authority with respect to the assets of OPI IV. Such authority includes the power of OrbiMed GP to vote and otherwise dispose of securities held by OPI IV. The number of outstanding Shares attributable to OPI IV is 2,437,967 Shares (which includes Shares issuable upon the exercise of warrants). OrbiMed Advisors, pursuant to its authority under the terms of the limited liability company agreement of OrbiMed GP, may be considered to hold indirectly 2,437,967 Shares (which includes Shares issuable upon the exercise of warrants). Investor Rights Agreement In addition, OPI IV and certain other stockholders of the Issuer entered into an amended and restated investor rights with the Issuer a summary of which is set forth at Item 6 of the Statement. Other than as described in this Amendment No. 4, to the best of the Reporting Per

Material to Be Filed as Exhibits

Item 7. Material to Be Filed as Exhibits Exhibit Description 1. Joint Filing Agreement among OrbiMed Advisors LLC and OrbiMed Capital GP IV LLC. 2. Investor Rights Agreement by and among the Issuer and each of the persons listed on Schedule A thereto, dated as of October 2, 2014 (incorporated by reference to Exhibit 4.2 to the Issuer's Registration Statement on Form S-1 (SEC 333-234217)). 3. First Amendment and Joinder to the Amended and Restated Investor Rights Agreement by and among the Issuer and each of the signatories thereto, dated as of October 23, 2017 (incorporated by reference to Exhibit 4.3 to the Issuer's Registration Statement on Form S-1 (SEC 333-234217)). Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: July 2, 2024 ORBIMED ADVISORS LLC By: /s/ Carl L. Gordon Name: Carl L. Gordon Title: Member ORBIMED CAPITAL GP IV LLC By: ORBIMED ADVISORS LLC, its managing member By: /s/ Carl L. Gordon Carl L. Gordon Title: Member of OrbiMed Advisors LLC SCHEDULE I The names and present principal occupations of each of the executive officers and directors of OrbiMed Advisors LLC are set forth below. Unless otherwise noted, each of these persons is a United States citizen and has a business address of 601 Lexington Avenue, 54th Floor, New York, NY 10022. Name Position with Reporting Person Principal Occupation Carl L. Gordon Member Member OrbiMed Advisors LLC Sven H. Borho German and Swedish Citizen Member Member OrbiMed Advisors LLC W. Carter Neild Member Member OrbiMed Advisors LLC Geoffrey C. Hsu Member Member OrbiMed Advisors LLC C. Scotland Stevens Member Member OrbiMed Advisors LLC David P. Bonita Member Member OrbiMed Advisors LLC Peter A. Thompson Member Member OrbiMed Advisors LLC Matthew S. Rizzo Member Member OrbiMed Advisors LLC Trey Block Chief

View Full Filing

View this SC 13D/A filing on SEC EDGAR